Wegovy vs Saxenda vs Mounjaro: Which Weight Loss Injection Is Right for You?

Choosing a prescription weight management treatment is about more than simply finding a medicine that may support weight loss. Today, eligible patients have several licensed prescription medicines available for weight management, each with its own active ingredient, dosing schedule, and treatment approach. Three of the most commonly compared prescription weight management medicines in the UK are Wegovy®, Saxenda®, and Mounjaro®.

Although all three medicines are prescribed to support weight management in appropriate patients, this guide explains the key differences between them. They differ in how often they are injected, the hormones they target, how dose escalation is managed, and the practical experience of using them over the long term.

If you are comparing Wegovy vs Saxenda vs Mounjaro, understanding these differences can help you have a more informed discussion with your prescriber. Rather than asking which medicine is "best", it is more useful to understand which treatment may be the most appropriate for your individual health needs, lifestyle, and clinical circumstances.

This guide compares the three medicines from both practical and clinical perspectives, helping you understand how they work, what makes each option different, and the factors healthcare professionals consider before prescribing them.

Quick Comparison: Wegovy vs Saxenda vs Mounjaro

Although Wegovy and Saxenda belong to the same medication class, they contain different active ingredients with different dosing schedules. Mounjaro differs further with a dual-action mechanism, targeting both GIP and GLP-1 receptors rather than GLP-1 alone.

These differences influence treatment planning, dose escalation, and the overall treatment experience because each medicine works differently .

Understanding the Three Active Ingredients

One of the biggest differences between these medicines lies in how they work inside the body.

Wegovy (Semaglutide)

Wegovy contains semaglutide, a GLP 1 receptor agonist that mimics a naturally occurring hormone released after eating. By activating GLP 1 receptors, it may help reduce appetite and slow gastric emptying, which may promote feelings of fullness, reduce food cravings, and help reduce calorie intake when combined with healthy lifestyle changes.

Semaglutide has a half life of around seven days, which supports its once weekly dosing schedule. This dosing schedule is one of the reasons Wegovy is widely used as a prescription weight management treatment in the UK.

Saxenda (Liraglutide)

Saxenda contains liraglutide, another GLP-1 receptor agonist. While it works through the same biological pathway as Wegovy, affecting appetite and the digestive system in a similar GLP-1-driven way, liraglutide has a shorter duration of action and a half-life of 24 hours in the body, which is why it requires daily injections instead of weekly administration.

For some patients, daily dosing provides a structured routine, while others may prefer a treatment that requires fewer injections throughout the month.

Mounjaro (Tirzepatide)

Mounjaro contains tirzepatide, which differs from both Wegovy and Saxenda because it activates two hormone pathways rather than one. It may also help support blood sugar control in appropriate patients.

It acts on:

GLP 1 receptors.

GIP (glucose dependent insulinotropic polypeptide) receptors.

This dual action mechanism represents a newer treatment approach and provides an additional option for healthcare professionals when considering individual patient needs. Tirzepatide is also licensed for the treatment of type 2 diabetes under separate indications.

Weekly vs Daily Injections: Which Fits Your Lifestyle?

One of the most noticeable differences between these medicines is how often they are administered.

Wegovy

Patients inject Wegovy once each week, usually on the same day every week. It is supplied as a pre-filled injection pen that makes weekly administration straightforward. This schedule helps many people establish a consistent routine while reducing the number of injections required each month.

Saxenda

Saxenda requires one injection every day. Although each injection is relatively straightforward, daily administration means patients need to remember treatment seven days a week.

Mounjaro

Like Wegovy, Mounjaro follows a weekly injection schedule, offering similar convenience for patients who prefer less frequent dosing.

For many people, reducing the number of injections can make long-term treatment easier to integrate into work schedules, family life, and travel.

Dose Escalation: How Treatment Progresses

All three medicines use gradual dose escalation, allowing the body to adapt before reaching the maintenance dose.

Wegovy Dose Escalation

• Weeks 1–4: 0.25mg
• Weeks 5–8: 0.5mg
• Weeks 9–12: 1mg
• Weeks 13–16: 1.7mg
• Week 17 onwards: 2.4mg

Saxenda Dose Escalation

Saxenda begins at 0.6mg daily before gradually increasing over several weeks until the maintenance dose of 3mg daily is reached.

Mounjaro Dose Escalation

Mounjaro starts at 2.5 mg once weekly and progresses through six licensed dose strengths, allowing healthcare professionals to tailor treatment according to individual response and tolerability. The dose is increased gradually until the maintenance dose or the highest clinically appropriate dose is reached.

The gradual dose increase used with each medicine is intended to help reduce the likelihood of gastrointestinal side effects during the early stages of treatment.

Comparing Everyday Convenience

Beyond clinical differences, practical considerations often influence which injectable weight management medicine feels easiest to use .

Some patients comparing weight loss injections focus on travel, scheduling, and ease of routine. Patients with demanding work schedules, frequent travel, or busy family commitments may appreciate the convenience of weekly injections, while others may feel comfortable incorporating a daily routine into their lifestyle.

Ultimately, convenience should be considered alongside clinical suitability, not as the only deciding factor.

Choosing the Right Treatment Starts with Clinical Advice

Although comparison articles can help explain the differences between Wegovy, Saxenda, and Mounjaro, the final treatment decision should always be based on a professional medical assessment.

Healthcare professionals consider several factors before recommending a treatment, including:

• Current body mass index (BMI).
• Existing medical conditions.
• Previous weight management attempts.
• Current medications.
• Personal treatment goals.
• Potential contraindications.
• Lifestyle and ability to follow the dosing schedule.

Rather than focusing only on which medicine appears to be the most popular, it is important to choose the treatment that best suits your individual health profile. This may also depend on whether you have a weight related health condition, such as high blood pressure or high cholesterol, as well as your overall treatment goals.

Clinical Evidence: What the Research Says

One of the most common questions patients ask is whether one medicine may lead to greater weight loss than another. While Wegovy, Saxenda, and Mounjaro have all been evaluated in large clinical studies and clinical trials, it is important to remember that these studies were conducted separately. Because the trials involved different patient populations, treatment durations, and study methods, the average weight loss results should not be interpreted as direct head to head comparisons.

Instead, each medicine has its own evidence base that supports its regulatory approval. This evidence can help set realistic expectations about the results that may be achieved.

Wegovy – STEP Clinical Trial Programme

Wegovy's effectiveness is supported by the internationally recognised STEP (Semaglutide Treatment Effect in People with Obesity) programme.

The landmark STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine (2021), reported that participants receiving Wegovy alongside lifestyle interventions achieved an average weight loss of approximately 15% of their initial body weight over 68 weeks, compared with 2.4% in the placebo group.

• Additional STEP studies demonstrated:
• Sustained weight management with continued treatment.
• Improvements in appetite regulation.
• Benefits when combined with a reduced calorie diet and increased physical activity.
• Long term maintenance of clinically meaningful weight loss in eligible patients.

The trial evidence also demonstrated clinically meaningful weight loss when Wegovy was used alongside lifestyle support.

These studies formed the scientific basis for Wegovy's approval for chronic weight management. Trial reporting also noted that 13.5% of participants receiving Wegovy discontinued treatment because of side effects.

Saxenda – SCALE Clinical Trial Programme

Saxenda was evaluated through the SCALE (Satiety and Clinical Adiposity Liraglutide Evidence) clinical trial programme.

The SCALE studies evaluated liraglutide 3 mg alongside lifestyle changes in adults living with overweight or obesity.

The research found that many participants achieved clinically meaningful weight loss compared with placebo while following structured dietary advice and increased physical activity.

In clinical trials, participants receiving Saxenda lost an average of about 8% of their body weight after 56 weeks. In the same trial setting, 27.6% of participants receiving Saxenda discontinued treatment because of side effects.

These studies also reported improvements in several weight related health markers when treatment was continued under medical supervision.

Mounjaro – SURMOUNT Clinical Programme

Mounjaro has been investigated through the SURMOUNT clinical trial programme for weight management, while the SURPASS programme primarily focused on adults with type 2 diabetes.

The available evidence suggests that tirzepatide may support substantial weight loss when combined with lifestyle changes. In clinical trial data, participants receiving Mounjaro lost up to 22.5% of their body weight over 72 weeks.

Some published analyses have reported greater average weight loss with Mounjaro than with Saxenda. However, these findings should be interpreted with caution because the studies used different designs and did not directly compare the two medicines. Treatment choice should always be based on clinical suitability. These findings have contributed to increased clinical interest in tirzepatide for weight management.

Because Mounjaro uses a dual GIP and GLP 1 receptor mechanism, researchers continue to evaluate its role in long term weight management across different patient populations.

As with all prescription weight management medicines, individual results vary depending on adherence, lifestyle, and clinical factors. Mounjaro was approved for weight management in November 2023.

Gastrointestinal side effects are commonly reported with both medicines, particularly during dose escalation. Some studies suggest these side effects may occur more frequently with tirzepatide than with liraglutide, although individual experiences vary.

For many patients, these symptoms are temporary and gradually improve as the body adjusts to treatment.

Healthcare professionals generally recommend following the prescribed dose escalation schedule rather than increasing doses too quickly, as this may help improve tolerability.

Serious side effects can include pancreatitis, gallbladder problems, and signs of a serious allergic reaction that require urgent medical attention.

Rapid weight loss with either medicine may also increase the risk of gallstones.

Patients who experience severe or persistent symptoms should seek medical advice promptly.

Storage and Travel Comparison

Practical considerations such as storage flexibility can influence everyday treatment experience, especially for patients who travel frequently or have busy lifestyles.

*Always follow the latest manufacturer's storage recommendations for your prescribed medicine.

Wegovy and Mounjaro are stored in much the same way before first use, despite different room-temperature time limits. Both Saxenda and Wegovy also require similar refrigerated handling before first use.

Wegovy's longer permitted room-temperature storage period may provide additional flexibility for some patients, particularly during holidays or business travel.

Pricing Comparison

Cost is another important factor when choosing between prescription weight management treatments. However, pricing should always be considered alongside clinical suitability, ongoing support, and the quality of the prescribing service.

At EverydayMeds, Wegovy is available with transparent pricing across every licensed dose, with no hidden consultation or prescription fees added after checkout.

Wegovy Pricing

Bundle options are also available for patients who wish to plan ahead for consecutive prescribed doses, subject to clinical review .

Because Saxenda and Mounjaro follow different dosing schedules and treatment pathways, overall treatment costs may differ throughout therapy. Your prescriber can help explain the expected cost based on your recommended treatment plan.

Which Treatment May Suit Different Patients?

There is no single weight management injection that is suitable for everyone. The most appropriate treatment depends on your medical history, lifestyle, and individual treatment goals, whether you are comparing Mounjaro vs Saxenda, Saxenda vs Wegovy, or Mounjaro vs Wegovy.

Wegovy may be suitable for patients who:

• Prefer a once-weekly injection.
• Want a medicine specifically licensed for weight management.
• Prefer a structured five-step dose escalation.
• Value extended room-temperature storage.

Saxenda may be suitable for patients who:

• Are comfortable with daily injections.
• Prefer gradual daily dose adjustments.
• Have been advised that liraglutide is appropriate for their clinical needs.

Mounjaro may be suitable for patients who:

• Prefer weekly dosing.
• Have been assessed as suitable for tirzepatide treatment.
• May benefit from a dual GIP and GLP-1 receptor approach, where clinically appropriate.

Only a qualified prescriber can determine which option is suitable after reviewing your medical history and treatment goals.

Comparison at a Glance

Rather than focusing on one medicine being "better," the goal is to identify the treatment that best aligns with your medical circumstances, lifestyle, and long-term weight management plan.

Choosing Between Wegovy, Saxenda and Mounjaro with EverydayMeds

Selecting the right prescription weight management treatment is about more than comparing active ingredients or prices. Your medical history, current health conditions, previous weight-loss attempts, medications, BMI, and treatment goals all influence which option may be appropriate. At EverydayMeds, every patient completes a comprehensive online clinical assessment before any prescription is considered, and it is designed to match patients with the right medication based on their health profile, preferences, and prescribing criteria.

Our qualified prescribers review each assessment individually, considering factors such as existing medical conditions, previous experience with GLP-1 medicines, potential contraindications, whether the treatment plan can support weight loss and, where relevant, help control blood sugar or support healthy blood sugar levels, and your long-term weight management objectives. This personalised approach helps ensure any treatment prescribed is appropriate for your individual circumstances while meeting UK prescribing standards.

From Assessment to Delivery: What to Expect

Getting started is straightforward and designed to fit around your schedule.

Step 1 – Complete Your Clinical Assessment

Begin with our secure online assessment, which takes around 3 minutes to complete. You'll be asked about:

• Your height and weight
• Medical history
• Current medications
• Previous weight management treatments
• Lifestyle factors
• Treatment goals

Step 2 – Prescriber Review

Once submitted, your assessment is reviewed by one of our qualified prescribers.

• Standard review: within 3 working days
• Express review: within 24 hours (where available)

Additional information may be requested if needed to ensure safe prescribing.

Step 3 – Prescription Approval

If clinically appropriate, your prescription is issued through our GPhC-registered pharmacy (#9012878) in accordance with MHRA regulations and UK prescribing guidance.

Step 4 – Temperature-Controlled Delivery

Approved orders are dispatched using specialist cold-chain packaging designed to maintain the required 2–8°C temperature throughout transit.

Your order includes tracking information so you can monitor delivery from dispatch to arrival

Why Patients Choose EverydayMeds

EverydayMeds aims to provide safe, transparent and clinically appropriate care throughout the treatment journey because we focus on safety, transparency, and continuity of care throughout the treatment journey.

What you can expect

• GPhC registered UK pharmacy (#9012878)
• Qualified UK prescriber review
• Genuine licensed medicines sourced through authorised UK wholesalers
• Transparent pricing with no hidden consultation fees
• Cold chain delivery with temperature monitoring
• Secure online ordering
• Ongoing support throughout dose escalation
• Guidance on once weekly injections and educational resources
• Multiple treatment options available in one place
• Reliable stock across the full Wegovy dose range

Our goal is to make medically supervised weight management straightforward and transparent while maintaining high clinical standards.